share_log
Breakings ·  Sep 18 19:30
Plus Therapeutics Showcases New Interim Respect-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment